Catalyst Pharmaceuticals, Inc. continued to forecast full year 2022 total revenues to be in the range of between $195 million and $205 million, representing a 38% - 45% increase in total revenues as compared to 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.62 USD | -0.89% | -3.40% | -7.08% |
06-05 | Catalyst Pharmaceuticals Insider Sold Shares Worth $276,735, According to a Recent SEC Filing | MT |
05-30 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.08% | 1.84B | |
+0.82% | 91.94B | |
-1.32% | 38.74B | |
-12.88% | 32.82B | |
+64.77% | 26.66B | |
-16.31% | 15.32B | |
-5.78% | 13.3B | |
-11.38% | 11.65B | |
+173.10% | 10.37B | |
-49.84% | 10.12B |
- Stock Market
- Equities
- CPRX Stock
- News Catalyst Pharmaceuticals, Inc.
- Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022